Loading...
XNAS
DYN
Market cap2.90bUSD
Dec 05, Last price  
20.28USD
1D
-1.79%
1Q
42.62%
IPO
-10.27%
Name

Dyne Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:DYN chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.69%
Rev. gr., 5y
%
Revenues
0k
3,103,000,0003,549,000,0002,468,000,0002,323,000,0001,585,000,0003,000,0003,000,0001,466,000,000842,000,0001,366,000,000506,000,0000000000
Net income
-317m
L+34.54%
264,000,000174,000,000-1,262,000,000-234,000,000-1,645,000,00087,000,000-356,000,000-67,000,00050,000,000-1,240,000,00076,000,000-4,811,000-13,536,000-58,737,000-149,283,000-165,237,000-235,937,000-317,418,000
CFO
-292m
L+55.38%
341,000,000319,000,000135,000,000423,000,000-20,000,000-44,000,000175,000,000-62,000,00094,000,000676,000,000585,000,000-4,164,000-11,834,000-46,508,000-119,563,000-153,645,000-188,158,000-292,369,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
URL
https://www.dyne-tx.com/
IPO date
Sep 17, 2020
Employees
134
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT